Alinea Pharmaceuticals has raised $45 million in its first round of venture capital to help fund research into treatments for diabetes and other metabolic disorders. MPM Capital led the round for the Cambridge, MA, based drug developer. Alinea also named Robert Marshal as its new president and CEO. Alinea's initial assets were licensed from the Institute for Diabetes Discovery in Branford, CT.
- read this article from the Boston Business Journal for more